GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Standard
GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. / Leggio, Lorenzo; Hendershot, Christian S.; Farokhnia, Mehdi; Fink-Jensen, Anders; Klausen, Mette Kruse; Schacht, Joseph P.; Simmons, W. Kyle.
I: Nature Medicine, Bind 29, Nr. 12, 2023, s. 2993-2995.Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders
AU - Leggio, Lorenzo
AU - Hendershot, Christian S.
AU - Farokhnia, Mehdi
AU - Fink-Jensen, Anders
AU - Klausen, Mette Kruse
AU - Schacht, Joseph P.
AU - Simmons, W. Kyle
N1 - Funding Information: The authors thank the following funding sources: NIDA and NIAAA Intramural Research Programs (L.L. and M.F.); NIAAA grant R21AA026931 and NIDA grant R21DA047663 (C.H.); the Research Fund of the Mental Health Services – Capital Region of Denmark (M.K.K.), the Novo Nordisk Foundation (M.K.K. and A.F.J.), NIAAA grants R01AA027765, R01AA026859, and R21 AA031146 (J.P.S.); the Hardesty Family Foundation (W.K.S.).
PY - 2023
Y1 - 2023
N2 - The development and rapid clinical adoption of potent and long-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) is quickly changing the landscape of diabetes and obesity treatment. In particular, semaglutide (marketed as Ozempic, Wegovy and Rybelsus) has attracted attention among the general public for its remarkable effects on weight loss. The explosive growth of its use in clinical practice has been accompanied by an important ancillary finding: frequent anecdotal reports of reductions in alcohol use and other addictive behaviors. These observations, which we have heard ourselves from patients and providers, are being amplified by media and public attention and have led to discussions about potential clinical applications of semaglutide and other GLP-1RAs for addictive disorders, especially alcohol use disorder (AUD). We write as leaders of clinical trials currently underway in North America and Europe to evaluate the efficacy of semaglutide for AUD to encourage clinicians and patients to be prudent and avoid placing supposition before science.
AB - The development and rapid clinical adoption of potent and long-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) is quickly changing the landscape of diabetes and obesity treatment. In particular, semaglutide (marketed as Ozempic, Wegovy and Rybelsus) has attracted attention among the general public for its remarkable effects on weight loss. The explosive growth of its use in clinical practice has been accompanied by an important ancillary finding: frequent anecdotal reports of reductions in alcohol use and other addictive behaviors. These observations, which we have heard ourselves from patients and providers, are being amplified by media and public attention and have led to discussions about potential clinical applications of semaglutide and other GLP-1RAs for addictive disorders, especially alcohol use disorder (AUD). We write as leaders of clinical trials currently underway in North America and Europe to evaluate the efficacy of semaglutide for AUD to encourage clinicians and patients to be prudent and avoid placing supposition before science.
U2 - 10.1038/s41591-023-02634-8
DO - 10.1038/s41591-023-02634-8
M3 - Comment/debate
C2 - 38001271
AN - SCOPUS:85177640091
VL - 29
SP - 2993
EP - 2995
JO - Nature Medicine
JF - Nature Medicine
SN - 1078-8956
IS - 12
ER -
ID: 377950036